At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 60 target
Drug / intervention
BPI-21668drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 in Advanced Solid Tumor Patients
In Brief
A Phase 1 clinical trial evaluating BPI-21668 for Advanced Solid Tumor. Targeting 60 participants across 1 site.
Detailed Summary
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-21668 in solid tumor patients. In dose escalation phase, biomarker status is not required, but in dose expansion phase patients are required to harbor PIK3CA mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
20222023202420252026
Enrollment StartJan 2022
First PostedApr 2022
Primary CompletionJan 2024
Study CompletionJan 2025
TodayJul 2026
First PostedApr 22, 2022
Enrollment StartJan 19, 2022
Primary CompletionJan 31, 2024
Study CompletionJan 31, 2025
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 4.2 years ago
Interventions
BPI-21668drug
Subjects will receive BPI-21668 until disease progression